<DOC>
	<DOC>NCT00349440</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of topical cyclosporine ophthalmic solution 0.05% (Restasis, Allergan) on the signs and symptoms of dry eye in patients undergoing LASIK or photorefractive keratectomy (PRK).</brief_summary>
	<brief_title>Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Males or females &gt; 18 years old Mildmoderate symptoms of dry eye prior to surgery Scheduled to undergo bilateral LASIK or PRK Likely to complete all study visits and able to provide informed consent Prior use of topical cyclosporine within the last 1 year Known contraindications to any study medication or ingredients Female of child bearing potential not using reliable methods of birth control, or pregnant or lactating females. Ocular disorders Active ocular diseases or uncontrolled systemic disease Active ocular allergies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Dry eye</keyword>
</DOC>